Regenerative Engineering Society Establishes Award in Honor of MIMEDX Board Member, Dr. Cato T. Laurencin
MARIETTA, Ga., Aug. 26, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today recognized Board Member, Cato T. Laurencin, M.D., Ph.D. for his leadership and contributions to advance the field of regenerative engineering. The Cato T. Laurencin Regenerative Engineering Founders’ Award has been established by the American Institute of Chemical Engineers (AIChE) Foundation and the AIChE Regenerative Engineering Society (RES) to recognize the accomplishments of individuals who have demonstrated leadership in the science and practice of convergence research as applied to regenerative engineering, a field pioneered by Dr. Laurencin.i The award additionally celebrates Dr. Laurencin’s impact on cultivating a more diverse and inclusive engineering and scientific community.
- This award celebrates his work and highlights the widespread impact and potential of researchers, educators, and mentors in this complex and emerging field.
- MIMEDX is committed to promoting scientific innovation and translational research that advances regenerative medicine and its potential to improve peoples health.
- The inaugural award will be presented in 2023 at the Regenerative Engineering Societys Annual Meeting.
- Dr. Laurencin is internationally renowned for his work in biomaterials, stem cell science, nanotechnology, drug delivery systems, as well the field of regenerative engineering.